105 related articles for article (PubMed ID: 17509947)
1. Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience.
Kirwan BA; Lubsen J; de Brouwer S; Danchin N; Battler A; Bayes de Luna A; Dunselman PH; Glasser S; Koudstaal PJ; Sutton G; van Dalen FJ; Poole-Wilson PA;
Contemp Clin Trials; 2007 Nov; 28(6):720-9. PubMed ID: 17509947
[TBL] [Abstract][Full Text] [Related]
2. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome.
Ruilope LM; Kirwan BA; de Brouwer S; Danchin N; Fox KA; Wagener G; Segura J; Poole-Wilson PA; Lubsen J;
J Hypertens; 2007 Aug; 25(8):1711-8. PubMed ID: 17620970
[TBL] [Abstract][Full Text] [Related]
3. Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: methodology and external validation.
Vranckx P; McFadden E; Cutlip DE; Mehran R; Swart M; Kint PP; Zijlstra F; Silber S; Windecker S; Serruys PW
Contemp Clin Trials; 2013 Jan; 34(1):53-9. PubMed ID: 22975439
[TBL] [Abstract][Full Text] [Related]
4. Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS. Gastro-Intestinal Therapeutic System.
Lubsen J; Poole-Wilson PA; Pocock SJ; van Dalen FJ; Baumann J; Kirwan BA; Parker AB
Eur Heart J; 1998 Aug; 19 Suppl I():I20-32. PubMed ID: 9743440
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs.
Pogue J; Walter SD; Yusuf S
Clin Trials; 2009 Jun; 6(3):239-51. PubMed ID: 19528133
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
Held C; White HD; Stewart RAH; Davies R; Sampson S; Chiswell K; Silverstein A; Lopes RD; Heldestad U; Budaj A; Mahaffey KW; Wallentin L;
Am Heart J; 2019 Feb; 208():65-73. PubMed ID: 30572273
[TBL] [Abstract][Full Text] [Related]
7. Quality management of a large randomized double-blind multi-centre trial: the ACTION experience.
Kirwan BA; Lubsen J; de Brouwer S; van Dalen FJ; Pocock SJ; Clayton T; Danchin N; Poole-Wilson PA;
Contemp Clin Trials; 2008 Mar; 29(2):259-69. PubMed ID: 18029294
[TBL] [Abstract][Full Text] [Related]
8. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]).
Carson P; Fiuzat M; O'Connor C; Anand I; Plehn J; Lindenfeld JA; Silver M; White M; Miller A; Davis G; Robertson AD; Bristow M; Gottlieb S
Am Heart J; 2010 Oct; 160(4):649-54. PubMed ID: 20934558
[TBL] [Abstract][Full Text] [Related]
9. Do we need to adjudicate major clinical events?
Granger CB; Vogel V; Cummings SR; Held P; Fiedorek F; Lawrence M; Neal B; Reidies H; Santarelli L; Schroyer R; Stockbridge NL; Feng Zhao
Clin Trials; 2008; 5(1):56-60. PubMed ID: 18283081
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions.
Lubsen J; Vokó Z; Poole-Wilson PA; Kirwan BA; de Brouwer S;
J Clin Epidemiol; 2007 Jul; 60(7):720-6. PubMed ID: 17573988
[TBL] [Abstract][Full Text] [Related]
11. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311
[TBL] [Abstract][Full Text] [Related]
12. The CAPTURE registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting.
Gray WA; Yadav JS; Verta P; Scicli A; Fairman R; Wholey M; Hopkins LN; Atkinson R; Raabe R; Barnwell S; Green R;
Catheter Cardiovasc Interv; 2007 Dec; 70(7):1025-33. PubMed ID: 18044758
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY.
Leonardi S; Branca M; Franzone A; McFadden E; Piccolo R; Jüni P; Vranckx P; Steg PG; Serruys PW; Benit E; Liebetrau C; Janssens L; Ferrario M; Zurakowski A; Diletti R; Dominici M; Huber K; Slagboom T; Buszman P; Bolognese L; Tumscitz C; Bryniarski K; Aminian A; Vrolix M; Petrov I; Garg S; Naber C; Prokopczuk J; Hamm C; Heg D; Windecker S; Valgimigli M
Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e006581. PubMed ID: 33535773
[TBL] [Abstract][Full Text] [Related]
14. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
Kang S; Yang Y; Li CJ; Gao R
Clin Ther; 2007 Nov; 29(11):2406-18. PubMed ID: 18158081
[TBL] [Abstract][Full Text] [Related]
16. Residual high-grade angina after enhanced external counterpulsation therapy.
McCullough PA; Henry TD; Kennard ED; Kelsey SF; Michaels AD;
Cardiovasc Revasc Med; 2007; 8(3):161-5. PubMed ID: 17765644
[TBL] [Abstract][Full Text] [Related]
17. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study.
Mahaffey KW; Harrington RA; Akkerhuis M; Kleiman NS; Berdan LG; Crenshaw BS; Tardiff BE; Granger CB; DeJong I; Bhapkar M; Widimsky P; Corbalon R; Lee KL; Deckers JW; Simoons ML; Topol EJ; Califf RM;
Curr Control Trials Cardiovasc Med; 2001 Jul; 2(4):187-194. PubMed ID: 11806794
[TBL] [Abstract][Full Text] [Related]
18. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis.
Ebrahimi R; Saleh J; Toggart E; Shah AP; Azmoon S; Babaei H; Lee J; Smith R; Movahed MR; Rubin SA
J Invasive Cardiol; 2008 Jun; 20(6):292-5. PubMed ID: 18523323
[TBL] [Abstract][Full Text] [Related]
19. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
20. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
